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ttp://dx.doi.org/10.1016/j.jmoldx.2014.06.009Prostate cancer is one of the leading causes of mortality among US males. There is an urgent unmet need
to develop sensitive and speciﬁc biomarkers for the early detection of prostate cancer to reduce over-
treatment and accompanying morbidity. We identiﬁed a group of differentially expressed long noncoding
RNAs in prostate cancer cell lines and patient samples and further characterized six long noncoding RNAs
(AK024556, XLOC_007697, LOC100287482, XLOC_005327, XLOC_008559, and XLOC_009911) in prostatic
adenocarcinoma tissue samples (Gleason score>6.0) and compared them with matched normal (healthy)
tissues. Interestingly, these markers were also successfully detected in patient urine samples and were
found to be up-regulated when compared with normal (healthy) urine. AK024556 (SPRY4-IT1) was highly
up-regulated in human prostate cancer cell line PC3 but not in LNCaP, and siRNA knockdown of SPRY4-IT1
in PC3 cells inhibited cell proliferation and invasion and increased cell apoptosis. Chromogenic in situ
hybridization assay was developed to detect long noncoding RNAs in primary prostatic adenocarcinoma
tissue samples, paving the way for clinical diagnostics. We believe that these results will set the stage for
more extensive studies to develop novel long noncoding RNA-based diagnostic assays for early prostate
cancer detection and will help to distinguish benign prostate cancer from precancerous lesions.
(J Mol Diagn 2014, 16: 615e626; http://dx.doi.org/10.1016/j.jmoldx.2014.06.009)Supported by NIH/National Cancer Institute grant 5P30CA030199
(R.J.P.) and the International Prostate Cancer Foundation (B.L.).
B.L. and J.M. contributed equally to the manuscript.
Disclosures: None declared.Despite advances associated with modern medicine, improve-
ments in prostate cancererelated mortality have been marginal
at best, and mortality has actually increased among obese Af-
rican American patients in recent years (http://www.cdc.gov/
cancer/dcpc/data/race.htm, last accessed September 9, 2014).
According to the2013NationalCancer Institute estimates, there
will be 238,590 new prostate cancer diagnoses this year; for
29,720 patients, it is likely to be fatal (http://www.cancer.org/
research/cancerfactsstatistics/cancerfactsﬁgures2013/index,
last accessed October 24, 2013). Although the incidence of
prostate cancer has been steadily increasing,1 with a concurrent
increase in surgical management with prostatectomy,2 moststigative Pathology
.men with prostate cancer have indolent disease for which
conservative therapy or an active surveillance approach would
be more appropriate and would result in less treatment-related
morbidity.3 A contributing problem has been the widespread
use of prostate-speciﬁc antigen (PSA) testing, which has low
speciﬁcity for cancer and cannot differentiate indolent and
aggressive cancers; this has resulted in large numbers of
Lee et alunnecessary biopsies and overtreatment.4,5 Therefore, there is a
signiﬁcant need for a speciﬁc prognostic biomarker that can
reﬁne existing diagnostic methods.
To address this need, several diagnostic and predictive
biomarkers are being actively investigated or are already in
clinical use,6 including the use of PSA isoforms, kallikreins,
and the measurement of the expression of several other genes
associated with prostate cancer (such as PCA3, GSTP1,
AMACR, ERG, and gene fusions that involve ETS-related
genes). In particular, PCA3, a long noncoding RNA
(lncRNA), has promise for the urinary detection of prostate
cancer with superior speciﬁcity to PSA.6e8
lncRNAs are RNA transcripts >200 nucleotides in length,9
many of which exhibit cell typeespeciﬁc expression10e12 and
are localized to speciﬁc subcellular compartments.13e17 A
number of lncRNAs are known to play important roles during
cellular development and differentiation,18e20 supporting the
view that they are under evolutionary selection.21e24 lncRNAs
can inﬂuence the expression of target proteins at speciﬁc
genomic loci,25e28 modulate the activity of protein-binding
partners,29e31 direct chromatin-modifying complexes to their
sites of action, and undergo posttranscriptional processing to
produce numerous 50-capped small RNAs.13,32 Like miRNAs,
lncRNAs are dysregulated in various medical conditions,
including heart disease,33,34 Alzheimer disease,35 psoriasis,36
and spinocerebellar ataxia type 8,37,38 as well as several can-
cers, such as breast cancer,19,39,40 colon cancer,41 prostate
cancer,42 hepatocellular carcinoma,43,44 and leukemia.43 We
recently found that lncRNA AK024556 (SPRY4-IT1) is up-
regulated in human melanomas and that siRNA-mediated
knockdown of SPRY4-IT1 in melanoma cells alters cellular
growth and differentiation and increases the rate of apoptosis.45
We report a group of prostate cancerespeciﬁc lncRNAs
that are up-regulated in prostate cancer cell lines and in
prostate cancer patient samples compared with nonmalig-
nant prostate epithelial and matched normal (healthy) pa-
tient prostate tissues. Six prostate cancer up-regulated
lncRNAs (AK024556, XLOC_007697, LOC100287482,
XLOC_005327, XLOC_008559, and XLOC_009911) were
characterized in prostatic adenocarcinoma tissue samples
(Gleason score >6.0) and compared with matched normal
tissues. We also found that these markers can be detected in
patient urine samples and that they are up-regulated when
compared with normal urine. Molecular function of one of the
up-regulated lncRNAs, AK024556, has been studied in detail
in prostate cancer PC3 cells and is reported here. Finally, we
believe that the results we report will lead to more extensive
studies to develop novel lncRNA-based diagnostic assays for
early prostate cancer detection.
Materials and Methods
Cell Lines
All experiments described in the manuscript used at least one
of the following human cell lines: prostatic epithelial cells616(ScienCell, HPrEpiC, catalog number 4410), PPC1, 22Rv1
(ATCC [Manassas, VA] CRL-2505), DU-145 (ATCC HTB-
81), LNCaP (ATCCCRL-1740), and PC3 (ATCCCRL-7934)
prostate cancer cell lines.
Prostate epithelial cells were grown in prostate epithelial cell
medium (ScienCell, PEpiCM, catalog number 4411), whereas
the prostate cancer cell lines were grown in Dulbecco’s modi-
ﬁed Eagle’s medium (Invitrogen, Carlsbad, CA), supplemented
with 10% fetal bovine serum and penicillin/streptomycin.
Microarray Experiments
The purity and integrity of the total RNA were analyzed on
RNA Nano chip (Agilent Technologies, Santa Clara, CA)
using the Eukaryote Total RNANano series protocol. The total
RNA was subjected to a single round of linear in vitro tran-
scription ampliﬁcation and labeled with Cy3-labeled cytidine
triphosphate using One-Color Low Input Quick Amp Labeling
Kit (Life Technologies, Grand Island, NY). The resulting Cy3
dye-incorporated antisense RNA was quantiﬁed using the ND-
1000 spectrophotometer (NanoDrop Technologies, Wilming-
ton, DE), and 600 ng of labeled antisense RNAwas hybridized
onto NCode human noncoding RNA (ncRNA) microarrays
(Life Technologies) or Agilent SurePrint G3 Human Gene
Expression version 2 arrays (Agilent Technologies). Three
replicates were used for each prostate cancer cell line and two
technical replicates for patient and normal pooled samples for
microarray experiments. After hybridization, the arrays were
washed following the manufacturer’s protocol using Gene
Expression Wash Pack (Agilent Technologies) and scanned
using the Agilent C Scanner. The intensities of the scanned
ﬂuorescence images were extracted with Agilent Feature
Extraction software version 10.7.3.1 (Agilent Technologies).
Microarray Data Analysis
The microarray data were normalized within and between
arrays by using the Linear Models for Microarray data
(LIMMA) package.46 The data were then normalized be-
tween arrays using the quantile approach. The duplicated
spots were treated as technical replicates using duplicated
correlation methods. Features (Probes) in 80% of arrays were
below the background (Agilent), ﬁltered out, and excluded in
further analyses. Therefore, probes with signals consistently
lower than the background across the samples were elimi-
nated. The mRNA and ncRNA features were separated based
on Agilent annotations. The empirical Bayes-moderated
t-statistics, which are implemented in the LIMMA Bio-
conductor package,46 were used for detection of the differ-
ential expression. The Benjamini and Hochberg approach
was used to control for false discovery.47 The lncRNAs with
fold-changes >2.0 and false discovery rate <0.05 were
considered as signiﬁcantly differentially expressed. The
hierarchical clustering and other statistical analyses were
performed using R/Bioconductor (http://www.r-project.
org).48 The data discussed in this publication have beenjmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 1 Screening of prostate cancererelated long noncoding RNA
(lncRNA) expression using microarrays. Alterations in lncRNA expression
proﬁles between prostatic epithelial cells and PC3 cells (NCode human
noncoding RNA microarray; Life Technologies) (A) and prostatic epithelial
cells, LNCaP, and PC3 cells (SurePrint G3 human lncRNA microarray; Agilent
Technologies) (B). Hierarchical clustering reveals distinguishable lncRNA
expression proﬁles. Red indicates high relative expression and green in-
dicates low relative expression. Numbers represent replicates.
lncRNAs as Prostate Cancer Biomarkersdeposited in Gene Express Omnibus (http://www.ncbi.nlm.
nih.gov/geo; accession number GSE55910).
RNA-FISH Analysis
A locked nucleic acidemodiﬁed probe for human
mRNA SPRY4 (50-GATGTTGCAACCACTGCCTGG-30)
containing a biotin label was used for RNAeﬂuorescence
in situ hybridization (FISH) analysis. Methods and pro-
tocols are cited in the article by Khaitan et al.45
RNA-CISH Analysis
Parafﬁn sections (5mm)and a prostate tissue array (USBiomax,
Inc., Rockville, MD) were placed on Ventana’s Discovery XT
platform (Ventana Medical Systems, Inc., Tucson, AZ) for
chromogenic in situ hybridization (CISH). The deparafﬁniza-
tionof thesectionswasperformedusing theprotocol selectedby
the instrument. All subsequent pretreatment steps were per-
formed on the Ventana platform using the FISH protocol and
Ventana-speciﬁc products. Ofﬂine detection staining was
accomplished using the alkaline phosphatase technique using
FastRedas a chromogen. The custom-made locked nucleic acid
probe with a dual FAM label from Exiqon was used during the
denaturing and hybridizing steps and was incubated for 4 hours
at the probe’s optimal temperature for annealing. Three separate
temperature-controlled stringency washes were performed to
wash away probe that was loosely bound. The primary rabbit
antiﬂuorescein antibody at a 1:100 dilution was applied with
heat for 1 hour followed by Ventana’s UltraMap antierabbit-
Alk Phos multimer detection for 20 minutes (no heat). The
chromogenic detection was performed ofﬂine using the com-
ponents of theVentanaChromoRedkit. Slideswere dehydrated
and coverslipped to complete the protocol. The prostate tissue
array was scanned using Aperio Scanscope (Aperio Technol-
ogies, Inc., Vista, CA). The tissue array cores were analyzed
using the NIS-Elements Imaging software version 4.20.00
(Nikon Instruments Inc., Melville, NY). The signal intensity of
staining and the total stained area were quantiﬁed with the
software. For each core, the mean intensity was calculated by
the sum of total intensity divided by the total stained area.
SPRY4-IT1 Knockdown in Prostate Cancer Cells,
Metabolic Viability Using the MTT Assay, and Invasion
Assays
SPRY4-IT1 knockdown in prostate cancer cells, metabolic
viability using the MTT assay, and invasion assays were
performed as previously described.45
Apoptosis (Caspase 3/7) Assays
PC3 cells were plated in 96-well plates at 5,000, 10,000, and
15,000 cells per well in triplicate for each transfection
condition (as above) and allowed to culture in Dulbecco’s
modiﬁed Eagle’s medium with 10% fetal bovine serum forThe Journal of Molecular Diagnostics - jmd.amjpathol.org48 hours before harvesting. Samples were then prepared
using the Caspase-Glo 3/7 assay kit (Promega, Fitchburg,
WI) and analyzed using a GloMax luminometer (Promega)
with conditions designed for the Caspase-Glo 3/7 Assay.617
Lee et alRNA Extraction and Quantitative Real-Time PCR of
Patient Tissue Samples
This study included a total of 28 tumors and matched normal
samples (Supplemental Table S1); 18 pairs of formalin-ﬁxed,
parafﬁn-embedded (FFPE) blocks; and 10 pairs of fresh
frozen samples of prostate cancer and adjacent normal tissues.
For the microarray experiments, 10 paired fresh frozen samples
were used. All 10 normal or 10 tumor patient tissues were
combined (separately), homogenized, and used for RNA puri-
ﬁcation using RNeasy FFPE kit (Qiagen, Valencia, CA).
All the tissue samples were collected at Florida Hospital
Celebration (Celebration, FL) between 2008 and 2012. The
use of tumor samples was approved by the institutional re-
view board of the Florida Hospital.
Next, 20 consecutive 18-mm sections were cut from each
patient block on a Leica 2235 microtome (Leica Micro-
systems, Buffalo Grove, IL) and placed into 2.0-mL micro-
centrifuge tubes. RNAwas extracted with an RNeasy FFPE kit
(Qiagen). RNA yield and A260/A280 ratio were monitored
with a NanoDrop ND-1000 spectrometer (NanoDrop Tech-
nologies). Preampliﬁcation was applied as described (TaqManTable 1 Summary of Up-Regulated lncRNAs Detected Using Microarray
Genes lgFC (PC/EP) lgFC (LN/EP) FDR PC
AF087978 5.8 4.61 
uc002llc 4.8 3.50 
EF177379 4.3 2.93 
BC013821 3.8 7.19 
uc001pyz 3.7 1.38 
AK024556* 3.7 7.19 
AB116553 3.5 6.44 
BC012900 3.5 1.29 
LOC100506303 2.6 5.1 0
LOC100506922y 3.6 4.9 0
LOC100287482* 3.0 4.8 0
XLOC_l2_009441 3.3 4.7 0
LOC154822 3.2 4.6 0.0188
XLOC_010807 3.5 4.5 0
XLOC_002335 3.4 4.5 0.0012
XLOC_l2_009136 2.1 4.4 2.00 
XLOC_002871 2.3 4.2 6.00 
ANKRD20A9Py 2.0 4.0 0
FLJ20444 4.1 4.0 0
XLOC_003734y 4.0 3.8 0
LOC100505666 2.1 3.7 2.00 
LOC100506411 4.1 3.5 0
XLOC_007697* 3.4 3.3 1.00 
XLOC_003734y 3.5 3.2 0
XLOC_l2_000735 4.6 2.8 2.00 
LOC100129480 4.5 2.4 0
XLOC_007162 3.1 2.2 0
LOC100506802 3.4 2.1 0
LOC100507025 5.7 2.1 0
XLOC_010813 3.8 2.0 0
*lncRNA expression was conﬁrmed in patient samples by quantitative real-time
ylncRNA expression could not be conﬁrmed in patient samples.
EP, prostate epithelial cells; FDR, false discovery rate; lgFC, log2 of fold chang
618PreAmp Master Mix kit, Life Technologies) and quantitative
real-time PCR (qPCR) performed as previously published.45
GAPDH was used as an endogenous control for tissues and
urine samples (Supplemental Figure S1).
Isolation of Total RNA from Urine Samples
Urine samples were obtained from patients with benign
prostatic hyperplasia, normal individuals, and patients with
prostate cancer and collected using preservation tubes
(Norgen Bioteck, Thorold, ON, Canada). Total RNA was
isolated from approximately 50 mL of urine using the
Urine (exfoliated cell) RNA puriﬁcation kit (Norgen Bio-
teck). lncRNA PCA3 was used as a positive control, and
GAPDH was used as the reference control for qPCR.
Results
lncRNA Transcripts Are Differentially Expressed in Prostate
Cancer Cell Lines and Normal Epithelial Prostate Cells
To identify which lncRNAs are differentially expressed in
prostate cancer, total RNA from prostate cancer cell liness in Prostate Cancer Cell Lines
vs EP FDR LN vs EP Genomic coordinates
109 chr5:92930109e92930169
108 chr18:70999788e71016350
108 chr11:65193353e65193413
109 chr5:480914e480974
109 chr11:123498414e123498474
109 chr5:141697230e141697290
109 chr1:79110307e79110367
107 chr8:29190671e29190731
0 chr14:19662601e19662660
0 chr2:128146912e128146971
0 chr7:129152443e129152502
0 chr22:16148038e16147979
76 0.002873 chr7:158815312e158815371
0 chr14:38208320e38208379
06 0.000238 chr2:138636416e138636357
106 0 chr21:15335073e15323443
105 1.00  106 chr3:149957932e149957991
0 chr13:19415809e19415750
0 chr9:66524045e66523986
0 chr4:152591561e152591620
106 0 chr1:155017772e155017713
0 chr14:71281913e71281972
106 1.00  106 chr9:044182789e044182730
0 chr4:152591414e152591473
106 3.80  105 chr1:1006425e1006366
0 chr3:12581659e12581600
0 chr8:95650283e95649930
1.00  106 chr3:50405569e50405628
0 chr6:26281345e26281286
0 chr14:041431994e041432050
PCR.
e; lncRNA, long noncoding RNA; PC, PC3; LN, LNCaP.
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Figure 2 Expression of the long noncoding RNAs (lncRNAs)
XLOC_007697 (A), LOC100287482 (B), and SPRY4-IT1 (C) as measured by
qPCR. The relative expression levels in ﬁve prostate cancer cell lines (PPC1,
22Rv1, DU-145, LNCaP, and PC3) and additional two prostatic epithelial
cells (Prostate Epi 2 and Prostate Epi 3) are compared with the expression
in prostatic epithelial cells (Prostate Epi 1). The Ct value of each lncRNA
was normalized to the Ct value of GAPDH, and the relative expression was
calculated by comparing with prostatic epithelial cells by calculating the
DDCt method. Data are expressed as means  SD from three biological
replicates for each cell line (AeC).
lncRNAs as Prostate Cancer Biomarkers
The Journal of Molecular Diagnostics - jmd.amjpathol.org(PC3, LNCaP) and normal epithelial prostatic cells were
screened using NCode human ncRNA array (Life Tech-
nologies) and SurePrint G3 human lncRNA microarrays
(Agilent Technologies). The NCode microarray is designed
to interrogate 12,784 lncRNAs and 25,409 mRNA target
protein-coding genes, whereas the SurePrint G3 Human
Gene array contains 16,472 lncRNAs and 34,127 mRNA
genes. There was an overlap of a small fraction of lncRNAs
between two arrays; thus, we decided to use both arrays to
conduct a comprehensive analysis of global lncRNA
expression in prostate cancer and normal epithelial cells.
Differentially expressed lncRNAs in prostate cancer cell
lines and normal cells are illustrated as hierarchical
clustering in Figure 1A (NCode Human Noncoding RNA
array) and 1B (SurePrint G3 Human Gene array); up-
regulated lncRNAs are listed in Table 1. The expression
levels of three top-ranking candidates (XLOC_007697,
LOC100287482, and AK024556) were conﬁrmed in pros-
tate cancer cell lines (PPC1, 22Rv1, DU-145) by qPCR
analysis in addition to PC3 and LNCaP cells (Figure 2). All
three lncRNAs were up-regulated in prostate cancer cell
lines compared with prostate epithelial cells. Comparison
with two additional normal prostate epithelial cells also
conﬁrmed the above results. lncRNA AK024556 (alias
SPRY4-IT1), was previously reported as being highly up-
regulated in human melanoma cells.45 qPCR results
further conﬁrmed that SPRY4-IT1 was up-regulated >100-
fold in PC3 cells compared with prostatic epithelial cells
(Figure 2C). Elevated expression of SPRY4-IT1 was also
seen in PPC1 cells, albeit to a lesser extent (<15-fold);
however, no expression was observed in LNCaP cells.
When compared, the expression patterns of SPRY4-IT1 to
SPRY4 (the open-reading frame in which SPRY4-IT1 isFigure 3 Expression of SPRY4-IT1 by RNAeﬂuorescence in situ hy-
bridization staining of prostatic epithelial LNCaP and PC3 cells. SPRY4-IT1
staining is in green (ﬂuorescein isothiocyanate) and nuclei are stained in
blue (DAPI).
619
Figure 4 Differential expression of the long noncoding RNAs (lncRNAs)
in human prostatic adenocarcinoma. A: Heat map shows differential lncRNA
expression between pooled prostate tumor samples and pooled adjacent
normal tissues. Each column represents the mean normalized signal intensity
values of two technical replicates from pooled normal and pooled tumor
samples. B: Five lncRNAs (XLOC_009911, XLOC_008559, XLOC_005327,
XLOC_007697, and LOC100287482) were selected on the basis of the
microarray results. The expression levels were measured in prostate tumor
samples (T) and matched normal tissues (N) by qPCR. DCt was calculated by
subtracting the Ct value of GAPDH from the Ct value of lncRNA. Graph shows
the DCt values of lncRNA. The lines inside the boxes denote the medians.
*P  0.05, Student’s t-test.
Table 2 Summary of Up-Regulated lncRNAs Detected Using
Microarrays in 10 Pairs of Primary Prostate Cancer Tissue Samples
and Adjacent Normal Tissues
Genes
lgFC
(T/N)
FDR T
vs N Genomic coordinates
XLOC_001699* 4.3 0.0154 chr2:147606877e147607878
XLOC_005327y 4.1 0.0137 chr6:53495838e53495897
LOC400958 3.9 0.0079 chr2:65129780e65129721
XLOC_008559y 3.7 0.0023 chr10:92749981e92750040
LINC00340 3.6 0.0129 chr6:22110999e22111058
XLOC_000495 3.6 0.0010 chr1:185532449e185590104
RPS18 3.3 0.0000 chr6:33244222e33244279
XLOC_012294 3.3 0.0008 chr17:67708680e67841626
XLOC_l2_008560 3.3 0.0000 chr20:18485441e18485738
XLOC_009911y 3.2 0.0003 chr12:121343059e121343118
*lncRNA expression could not be conﬁrmed by quantitative real-time PCR.
ylncRNA expression was conﬁrmed by quantitative real-time PCR.
FDR, false discovery rate; lgFC, log2 of fold change; lncRNA, long non-
coding RNA; N, normal; T, tumor.
Lee et alembedded) were similar, with PC3 cells suggesting a
coordinating expression (Supplemental Figure S2A). RNA-
FISH results (Figure 3 and Supplemental Figure S2B)
conﬁrmed that both SPRY4-IT1 and SPRY4 could be
detected in PC3 cells, consistent with the qPCR results.
Differentially Expressed lncRNAs in Prostate Cancer
Patient Samples and Matched Normal Tissue
To identify global lncRNA expression proﬁles in prostate can-
cer, we have investigated lncRNA expression in prostate cancer
tissue samples and matched normal tissues. Ten paired (tumor
and adjacent normal tissue) frozen biopsy specimens were ob-
tained, and total RNA was assayed using the SurePrint G3620Human Gene Expression version 2 microarray. Hierarchical
clustering of the differentially expressed lncRNAs is shown in
Figure 4A, and top up-regulated lncRNAs are listed in Table 2.
Several differentially expressed lncRNAs (XLOC_009911,
XLOC_008559, andXLOC_005327)were conﬁrmedbyqPCR
using an additional set of prostate cancer tissue samples (18
paired tumors and adjacent normal tissue, FFPE) (Figure 4B).
XLOC_008559 is located on chr10:92749981-92750040,
whereas the other two lncRNAs are located on chr6, and
chr12, respectively, in large intergenic regions (Table 2). The
expression values of XLOC_008559, XLOC_005327, and
XLOC_009911 were all signiﬁcantly higher in prostate tumor
tissues (Figure 4B) compared with matched normal tissues. In
addition, two of the candidates identiﬁed from the cell line data
(XLOC_007697 and LOC100287482) were also validated in
patient samples (Figure 4B).
As expected, we noticed that genes differentially
expressed in patient samples did not have a similar expres-
sion pattern in cell lines. In total, we identiﬁed 59 differen-
tially expressed lncRNAs in patient samples compared with
matched normal tissues. The signiﬁcant lncRNAs are listed in
Supplemental Table S2. We are primarily focusing on the up-
regulated lncRNAs as putative biomarkers in prostate tumor
compared with matched normal tissues. However, down-
regulated genes in patient samples compared with matched
normal tissues, as well as prostate cancer cell lines compared
with normal prostate epithelial cells, can be obtained from the
raw data submitted to the GEO database (http://www.ncbi.
nlm.nih.gov/geo; accession number GSE55910).
lncRNAs Can Be Detected in Patient Urine Samples
To determine whether six prostate cancer up-regulated
lncRNAs (AK024556, XLOC_007697, LOC100287482,
XLOC_005327, XLOC_008559, and XLOC_009911) identi-
ﬁed in this study also can be detected in patients’ urine samples,jmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 6 Differential expression of AK024556 (SPRY4-IT1) in human
prostatic adenocarcinoma. A: The expression level of SPRY4-IT1 was measured
by qPCR in 18 paired prostate tumor and normal samples. DCt was calculated
by subtracting the Ct value of GAPDH from the Ct value of long noncoding RNA.
B: The expression level of SPRY4-IT1 in patient samples measured by droplet
digital PCR (ddPCR). The lines inside the boxes denote themedians. *P 0.05,
***P  0.001, Student’s t-test.
Figure 5 Detection of long noncoding RNAs (lncRNAs) up-regulated in
urine samples in prostate cancer. Expression of six lncRNAs (SPRY4-IT1,
XLOC_007697, LOC100287482, XLOC_009911, XLOC_008559, and
XLOC_005327) was measured by qPCR in 14 normal and 13 prostate cancer
patients. DCt was calculated by subtracting the Ct value of GAPDH from the
Ct value of lncRNA. The lines inside the boxes denote the medians. The
expression of all six lncRNAs was signiﬁcantly higher in prostate cancer
patients. *P  0.05, **P  0.01, Student’s t-test. N, normal patient; T,
prostate cancer patient.
lncRNAs as Prostate Cancer Biomarkerswe performed qPCR using total RNA isolated from urine. The
urine total RNA was isolated from 13 prostate cancer patients
and 14 healthy individuals. All six lncRNAs, including PCA3
(positive control lncRNA), were found to be statistically
signiﬁcantly up-regulated in the urine samples obtained from
the prostate cancer patients compared with the normal patient
controls (Figure 5). We next measured the expression of these
lncRNAs in benign prostatic hyperplasia patients and observed
that there was no signiﬁcant expression difference between
normal and benign prostatic hyperplasia patient samples
(Supplemental Figure S3).
SPRY4-IT1 Is Up-Regulated in Primary Human Prostatic
Adenocarcinomas Compared with Matched Normal
Tissues
SPRY4-IT1 expression levels were measured by qPCR in a
total of 18 prostatic adenocarcinoma tissue samples and
matched normal prostate tissues. SPRY4-IT1 was up-
regulated in cancerous tissue (Figure 6A), with its expres-
sion increasing in 16 of 18 cancer cases (89%) relative to
paired normal tissue samples. The expression of SPRY4-IT1
was further conﬁrmed using a droplet digital PCR (ddPCR)
system, which has the advantage of being able to detect
target molecules in very small quantities of sample RNA.
This is particularly important for FFPE tissue samples
because the recovery efﬁciency of total RNA from FFPE is
generally poor. Using ddPCR, we conﬁrmed the up-
regulation of SPRY4-IT1 in tumor compared with matched
normal tissues (Figure 6B). Although the exact relative
expression levels of SPRY4-IT1 measured by ddPCR were
not identical to qPCR values, the overall pattern of SPRY4-
IT1 expression in each patient sample remained the same
(Supplemental Table S3). Both SPRY4-IT and SPRY4 hadThe Journal of Molecular Diagnostics - jmd.amjpathol.orgelevated expression in tumor tissues (Supplemental
Figure S4).
RNA-CISH Conﬁrms that SPRY4-IT1 Expression Is
Speciﬁc to Prostate Cancer Patients
Because SPRY4-IT1 is highly expressed in primary prostatic
adenocarcinomas, we decided to visualize SPRY4-IT1
expression by RNA CISH to facilitate future clinical use.
For the initial RNA-CISH study, two prostate cancer and
matched normal tissue FFPE samples were selected. The
results revealed that there was a signiﬁcant expression dif-
ference between the tumors and matched normal tissues by
the strong staining seen in malignant glands, but not in
normal prostatic glands, by RNA-CISH (Figure 7, A and B).
We next performed RNA-CISH on a prostate cancer tis-
sue array to conﬁrm the speciﬁcity of expression in prostatic
adenocarcinoma and to assess associations with Gleason
grading. SPRY4-IT1 expression was easily detected in all
adenocarcinoma samples [Gleason scores 6 (3 þ 3), 7
(3 þ 4 and 4 þ 3), 8 (4 þ 4), 9 (5 þ 4 and 4 þ 5), and 10
(5 þ 5)] (Figure 7C), whereas there was almost no staining
in normal prostatic tissue. Tumor tissues had signiﬁcantly
higher staining intensity compared with adjacent normal621
Figure 7 RNAechromogenic in situ hybridi-
zation (CISH) analysis of SPRY4-IT1. A: RNA-CISH
staining of SPRY4-IT1 in tumor samples and
matched normal tissues [formalin-ﬁxed, parafﬁn-
embedded (FFPE) samples]. Expression was visu-
alized using alkaline phosphatase-labeled probes.
B: qPCR of SPRY-IT1 expression in tumor and
matched tissue samples (FFPE samples in A). C:
RNA-CISH staining of SPRY4-IT1 expression in
human prostate cancer tissue array. Tissue sam-
ples include normal prostate, adjacent normal,
and prostate cancer samples indicated by Gleason
scores: 6 (3þ 3), 7 (3þ 4 and 4þ 3), 8 (4þ 4), 9
(5 þ 4 and 4 þ 5), and 10 (5 þ 5). Expression is
visualized using alkaline phosphatase-labeled
probes. Scale bar Z 100 mm (A). N, normal pa-
tient; T, prostate cancer patient.
Lee et altissues. A quantitative analysis of the tissue array further
conﬁrmed the higher staining intensity in tumor tissues
compared with normal tissues (Supplemental Figure S5 and
Supplemental Table S4). These results indicate that SPRY4-
IT1 expression is speciﬁc to adenocarcinoma and can be
detected using standard clinical staining procedures.
Molecular Function of SPRY4-IT1 in Prostate Cancer
Cells
The loss of SPRY4-IT1 in melanoma was previously found to
reduce proliferation and invasion and to increase apoptosis.45
We knocked down SPRY4-IT1 using siRNA, and the results
indicated that approximately 40% knockdown was achieved
after 48 hours at both 100 nmol/L and 200 nmol/L siRNA
concentrations (Figure 8A). In knockdown cells, there was
approximately 50% loss of cell viability compared with nega-
tive controls (Figure 8B). Furthermore, a cell invasion assay
performed using standard Boyden chambers indicated that cells
transfected with SPRY4-IT1 siRNA had signiﬁcant defects in
cell invasion, with cell counts equal to 50% of control at 100
nmol/L and 40% of control at 200 nmol/L (Figure 8, C and D).
Finally, apoptosis was assessed by measuring the caspase 3/7
activity in siRNA-transfected PC3 cells, revealing a 50%622increase in activity at 100 nmol/L and an approximately 60%
increase at 200 nmol/L compared with controls (Figure 8E).
Together, these results indicate that loss of SPRY4-IT1 in
prostate cancer cells leads to decreased cell viability and cellular
invasion and to increased apoptosis, similar to what has been
reported previously in melanoma cells.Discussion
Digital rectal examination and prostate-speciﬁc antigen are
the most commonly used screening methods for prostate
cancer. However, several advisory groups now recommend
against the use of prostate-speciﬁc antigen tests because the
beneﬁts of this diagnostic tool are, at best, small.49,50 Thus,
there is an urgent unmet need for novel and accurate diag-
nostic biomarkers for prostate cancer. We systematically
proﬁled lncRNA expression in three distinct groups: i)
prostate cancer cell lines and normal prostate epithelial cells,
ii) prostate cancer patient samples and matched normal tis-
sue samples, and iii) patient-derived urine and urine from
healthy individuals. To comprehensively search for differ-
entially expressed lncRNAs in prostate cancer and normal
prostate tissues, we used two distinct microarrays (NCodejmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 8 SPRY4-IT1 knockdown effect on PC3 cells. PC3 cells were treated with siRNA duplexes to SPRY4-IT1 or with a scramble control siRNA (Scr siRNA) at either
100 or 200 nmol/L. The amount of SPRY4-IT1 transcript was analyzed by quantitative real-time PCR at 48 hours after transfection. A: Relative RNA expression was
determined using GAPDH control to untransfected cells. B: Loss of SPRY4-IT1 affects PC3 cell viability by MTT assay. C: A signiﬁcant decrease in the viability of PC3
cells was observed after 48 hours of SPRY4-IT1 siRNA transfection. Knockdown of SPRY4-IT1 resulted in suppressing PC3 cells invasion. PC3 cell invasion after 48 hours
transfection with siRNA. D: Staining of PC3 cells (crystal violet) after 48 hours transfection with SPRY4-IT1 siRNA to show the decrease of cell invasion. E: Apoptosis
measured by caspase 3/7 activity in PC3 cells 48 hours after transfection with SPRY4-IT1 siRNA. Results are expressed as means SD of three experiments and are
presented as a bar graph after normalizing to the untransfected control. ***P  0.001 compared with the untransfected control.
lncRNAs as Prostate Cancer Biomarkersand SurePrint G3), allowing us to maximize the coverage of
lncRNA expression proﬁling.
We report thatAK024556,XLOC_007697,LOC100287482,
XLOC_005327, XLOC_008559, and XLOC_009911 are up-
regulated in prostate cancer patient samples and cell lines and
also elevated in patient urine samples compared with matched
normal tissues, prostate epithelial cells, and urine from healthy
individuals.
Recently, several lncRNAs have been reported to be dysre-
gulated in prostate cancer, including PCGEM1, PCAT-1,
PRNCR1, andPCA3.51PCA3 is highly expressed in almost 95%
of primary prostate tumors52 and is the most advanced lncRNA
in prostate cancer clinical diagnostics. Progensa’s PCA3 urine
test is highly speciﬁc and has been approved by the Food and
Drug Administration for clinical decision making regarding
when to perform additional biopsies in men with previously
negative biopsy results. However, there remain discrepancies
between PCA3 levels and clinicopathologic features (such as
tumor volume, Gleason grade, or poor prognostic factors, such
as extracapsular extension) in validation studies.53e56 There-
fore, althoughPCA3 remains a promising diagnostic biomarker,
its role in predicting the occurrence of prostate cancer can be
improved with lncRNA markers reported in this study and also
when PCA3 is combined with other molecular markers, such as
the TMPRSS2-ERG fusion gene.57The Journal of Molecular Diagnostics - jmd.amjpathol.orgWith increasing awareness of the varied roles of lncRNAs
in cancer biology, it is apparent that lncRNAs can be clas-
siﬁed as either oncogenes or tumor suppressor genes,
depending on type and context. lncRNAs known to function
as tumor suppressors include MEG3, GAS5, LincRNA-p21,
PTENP1, TERRA,CCND1 (cyclin D1), and TUG1 (reviewed
by Nie et al58). Some lncRNAs, such as PCGEM1, PINC,
KRASP, HULC, HOTAIR,MALAT1/NEAT1, p15AS, ANRIL,
H19, SRA1, and RICTOR, regulate critical oncogenic cell
signaling pathways (reviewed by Nie et al58). For example,
PCGEM1 was one of the ﬁrst oncogenic lncRNAs identiﬁed
and is highly expressed in prostate cancer tissues,59 and
overexpression of PCGEM1 in LNCaP cells promotes cell
proliferation and increased colony formation.60
AK024556, also known as SPRY4-IT1, was ﬁrst identiﬁed as
a melanoma up-regulated lncRNA; it is highly expressed in
melanoma cell lines and patient samples45 compared with
normal human melanocytes and benign melanocytic nevi.
Knock down of SPRY4-IT1 using siRNA in A375 melanoma
cells decreases both cell proliferation and invasiveness and
increases apoptosis. Ectopic expression of SPRY4-IT1 in LOX-
IMV1 cells (cell line that shows a low SPRY4-IT1 expression)
increases motility.45 Similar phenotypes were also observed in
prostate cancer cells (PC3) when SPRY4-IT1 was knocked
down by siRNA.623
Lee et alThe expression of all six tested lncRNAs was higher in
prostate tumors compared with matched normal tissue,
indicating the potential of using these lncRNAs to suc-
cessfully distinguish cancerous from normal tissues. Inter-
estingly, we observed an elevated lncRNA expression in
some of the normal matched tissues, suggesting a possible
contamination. An alternate explanation for this observation
(elevated lncRNA expression in adjacent normal tissues) is
that we observed the early transformation and spreading of
prostate cancer to neighboring tissues that could not be
detected by conventional histopathologic techniques.
PCA3 has already been used in large screening (urine)
programs.61 However, at present there is no evidence of other
urine-based lncRNAmarkers for prostate cancer diagnostics.
The six differentially expressed genes reported in this study
were assessed for urine-based testing, and all six were found
to be statistically signiﬁcantly elevated in their expression
levels in the urine of prostate cancer patients compared with
normal individuals’ urine. However, the results reported here
must be validated in a large patient cohort before assigning
their use as biomarkers; we are further investigating it in our
laboratory. Interestingly, in our study, PCA3 was not detec-
ted in all the tested patients’ samples, which highlights the
insufﬁciency and risks of depending on a single biomarker
for prostate cancer detection. In this regard, combining
additional markers may increase the speciﬁcity and the
sensitivity of current prostate cancer molecular marker
testing. Thus, the use of multiple biomarkers for cancer
detection can overcome the limitation of single-marker de-
ﬁciencies and could improve the accuracy of testing.62,63
In conclusion, we have identiﬁed a set of lncRNAs that
are aberrantly expressed in primary prostate cancers and
prostate cancer cell lines, which appear to have an important
role in prostate cancer diagnostics.
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